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1. INTRODUCTION 
I did my bibliographic research 
using NCBI (national center for 
biotechnology information) 
searching for articles and reviews 
in PubMed data base. For the 
selection I only choose articles 
from 2012 and later with an 
exception for the ethical issues 
which is from 2010.  
The search was limited to English 
language publications.  
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1. The Technique 
There are currently two primary next generation sequencing approaches for gathering 
genetic data from cfDNA. The first, massively parallel shotgun sequencing (MPSS), 
sequences DNA fragments from the whole genome, whereas the second, targeted 
sequencing (TS), selectively sequences specific genomic regions.  
 
 Allelic ratio: Assume that both alleles are transcribed at  
         an equal rate and quantify SNPs  RT-PCR and mass  
         spectrometry 
Restrictions: heterozygous fetuses and monosomies 
 Chromosome dose: Next generation sequencing is the  
         most promising and it works with the principal that in a  
         normal fetus the ratio of two chromosomes sholud be 2:2. It is polymorphism-
independent.  
 
 Sex determination for high risk of X-linked diseases: TS of Y chromosome 
sequences, most commonly SRY or DYS14. It has reduced the need for invasive 
testing by 45%. 
 Determining Rh blood type: Best results achieved by qRT-PCR for exons 4, 5 and 10 
of RHD gene. 
   
 The use of MPSS and the prediction about inheritance of haplotype blocks from 
parental genomes as they are not inherited as independent sites allows grater 
statistical power. Identification of fetal de novo mutations, microdeletions and 
genetic disease screening are possible. 
Restrictions:  epigenetic modifications and twin pregnancies 
 
 
 
2. Data Analysis and Interpretation 
The z-score reflects the number of standard deviations the proportion of reads from a 
particular chromosome (in relation to the proportion of reads from all other 
chromosomes) is above the mean.  
Z-score > 2 .5  trisomy 
The score does not account for the variation in GC base content from chromosome caused 
by the different polymerase chain reaction conditions. To solve this, some approaches 
have been made: 
 Z-score with GC correction 
 Z-score with GC correction using an internal control 
 
3. Commercial landscape 
 
 
 
 
 
  NIPT is playing and will increasingly play an important role in the future practice of 
prenatal testing and it is in constant development.  
It has three main applications;  X-linked diseases, Aneuploidies and Whole fetal Genome 
Recovery which is the most revolutionary and controversial  
  Data analysis and interpretation are a key factor for the technique effectiveness and 
efficacy. 
  Competition between companies can be a great incentive for the technique 
improvement but also a hurdle because of IP (intellectual propriety) issues.  
  MPSS will be available and effective for all fetal aneuploidies, sub-chromosomal 
deletions and duplications, monogenic disorders and eventually the entire fetal genome.  
  There is a need to address the ethical, legal and social issues surrounding such 
developments and the placental origin of the DNA.  
  Guidelines from several professional societies now exist to aid women’s healthcare 
providers in determining under which circumstances patients should be offered such 
testing.  
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All started in 1997 with the discovery of cell-free DNA (cfDNA) fragments of fetal Y-chromosome in the plasma of 
pregnant women with male fetuses. The door for the development of non-invasive prenatal testing (NIPT) using 
maternal blood was opened to be thoroughly passed through sparking a new phase of innovation.  
 
NIPT, is a sophisticated blood test that examines fetal DNA in the maternal bloodstream to determine whether the 
baby is at risk of Down syndrome, extra sequences of chromosome 13, chromosome 18 or a sex chromosome 
abnormality, such as Turner syndrome. The testing can also be used to determine a baby's sex, rhesus (Rh) type 
and a whole genome recovery by massive parallel sequencing. Fetal DNA can be detected in as little as 10 µL of 
maternal plasma and serum from as early as four gestational weeks.  
NIPT has higher detection rates than the invasive techniques and the risks are lower, that is why it is increasing the 
interest not only of doctors, researchers and parents but also of businessmen.  
 
The American Congress of Obstetricians and Gynecologists and other organizations recommend cfDNA testing 
only for high-risk pregnancies, and specify that abnormal results should be confirmed by invasive testing before 
any action is taken.  
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